List of hallucinogen scales

This is a list of hallucinogen scales, or psychometric scales used to assess the subjective effects of hallucinogens, such as psychedelics like LSD, psilocybin, mescaline, and dimethyltryptamine (DMT), as well as other hallucinogens like ketamine and salvia.[1][2][3][4][5] They include:[1][2][3][4][5]

  • Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
  • Addiction Research Center Inventory (ARCI)
  • After the Spiritual Experience Questionnaire (ASEQ)
  • Altered States of Consciousness Rating Scale (ASC)
  • Challenging Experience Questionnaire (CEQ)
  • Clinician-Administered Dissociative States Scale (CADSS)
  • Drug Effects Questionnaire (DEQ)[8]
  • Ego Dissolution Inventory (EDI)
  • Emotional Breakthrough Inventory (EBI)
  • Hallucinogen Rating Scale (HRS)
  • Higher Consciousness Scale (HC-18)[9]
  • Hood Mysticism Scale (HMS; M-scale)
  • Mystical Experience Questionnaire (MEQ)
  • Mystical Orientation Scale (MOS)
  • Near-Death Experience Questionnaire (NDE)
  • Phenomenology of Consciousness Inventory (PCI)
  • Psychedelic Experience Scale (PES)[10]
  • Psychological Insight Questionnaire (PIQ)
  • Psychological Insight Scale (PIS)
  • Psychotomimetic States Inventory (PSI)
  • Short Index of Mystical Orientation (SIMO)
  • Shulgin Rating Scale (SRS)[11]
  • States of Consciousness Questionnaire (SOCQ)
  • Swiss Psychedelic Side Effects Inventory (SPSI)[12]
  • Watts Connectedness Scale (WCS)[13]
  • Wave test (WAVE)[14]

Some of these scales are broad/general scales, while others are more narrow and focused on specific aspects of experiences.[1][2][3][4][5]

Among the most widely used scales include the 5D-ASC, 11-ASC, HRS, MEQ, and SOCQ.[1][2][3][4]

See also

References

  1. 1 2 3 4 5 de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, Tófoli LF, Daldegan-Bueno D (2023). "Systematic Review of Psychometric Instruments Used in Research with Psychedelics". J Psychoactive Drugs. 55 (3): 359–368. doi:10.1080/02791072.2022.2079108. PMID 35616606.
  2. 1 2 3 4 5 Prugger J, Derdiyok E, Dinkelacker J, Costines C, Schmidt TT (November 2022). "The Altered States Database: Psychometric data from a systematic literature review". Sci Data. 9 (1): 720. doi:10.1038/s41597-022-01822-4. PMC 9684144. PMID 36418335.
  3. 1 2 3 4 Herrmann Z, Earleywine M, De Leo J, Slabaugh S, Kenny T, Rush AJ (2023). "Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials". J Psychoactive Drugs. 55 (4): 501–517. doi:10.1080/02791072.2022.2125467. PMID 36127639.
  4. 1 2 3 4 Hovmand OR, Poulsen ED, Arnfred S (January 2024). "Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics". J Psychopharmacol. 38 (1): 19–32. doi:10.1177/02698811231200019. PMC 10851631. PMID 37969069.
  5. 1 2 3 Costines C, Schmidt TT (December 2024). "Phenomenology of Psychedelic Experiences and Psychedelic-Associated Distressing Effects: Quantifying Subjective Experiences". Curr Top Behav Neurosci. doi:10.1007/7854_2024_562. PMID 39739177.
  6. ↑ Studerus E, Gamma A, Vollenweider FX (August 2010). "Psychometric evaluation of the altered states of consciousness rating scale (OAV)". PLoS One. 5 (8) e12412. doi:10.1371/journal.pone.0012412. PMC 2930851. PMID 20824211.
  7. ↑ Stocker K, Hartmann M, Schmid Y, Vogt SB, Becker AM, Ley L, Straumann I, Arikci D, Klaiber A, Erne L, Vizeli P, Holze F, Liechti ME (December 2025). "The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research". J Psychopharmacol 2698811251397328. doi:10.1177/02698811251397328. PMID 41451514.
  8. ↑ Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS (May 2013). "The drug effects questionnaire: psychometric support across three drug types". Psychopharmacology (Berl). 227 (1): 177–192. doi:10.1007/s00213-012-2954-z. PMC 3624068. PMID 23271193.
  9. ↑ Molina, Miguel D.; Molina, Linda; Zappaterra, Mauro W. (11 September 2025), Development and validation of the higher consciousness scale (HC-18): A new and integrated measure of transcendent experiences, doi:10.31219/osf.io/cgb6e_v4, retrieved 30 March 2026
  10. ↑ Stocker K, Hartmann M, Ley L, Becker AM, Holze F, Liechti ME (January 2024). "The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies". J Psychopharmacol. 38 (1): 80–100. doi:10.1177/02698811231199112. PMC 10851635. PMID 37905369.
  11. ↑ Shulgin AT, Shulgin LA, Jacob P (May 1986). "A protocol for the evaluation of new psychoactive drugs in man" (PDF). Methods Find Exp Clin Pharmacol. 8 (5): 313–320. PMID 3724306.
  12. ↑ Calder AE, Hasler G (November 2024). "Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA". J Affect Disord. 365: 258–264. doi:10.1016/j.jad.2024.08.091. PMID 39168165.
  13. ↑ Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L (November 2022). "The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world". Psychopharmacology (Berl). 239 (11): 3461–3483. doi:10.1007/s00213-022-06187-5. PMC 9358368. PMID 35939083.
  14. ↑ URV, Repositori; Ona, Genis (1 January 2020). "Development and Validation of a Questionnaire to Detect the Risk of Serious Adverse Reactions Due to the Use of Psychedelic Drug in Therapy". International Journal Of Psychology And Psychological Therapy (in Catalan). Retrieved 30 March 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.